10.07.2015 Views

220-Dictionary of Pharmaceutical Medicine, 2nd Edition-Gerhard Nahler Annette Mollet-3211898352-S

220-Dictionary of Pharmaceutical Medicine, 2nd Edition-Gerhard Nahler Annette Mollet-3211898352-S

220-Dictionary of Pharmaceutical Medicine, 2nd Edition-Gerhard Nahler Annette Mollet-3211898352-S

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

106lifprotection; since costs <strong>of</strong> launching and establishing a new productare far greater than the costs <strong>of</strong> maintaining one already onthe market there is a strong case for consciously extending the life<strong>of</strong> a product for as long as possible; increasing costs for R&D andbudget pressure on public health systems tend also to favour wellestablisheddrugs for standard therapy; potency and side effectsare <strong>of</strong>ten acceptable, whereas delivery and bioavailability may beless satisfactory; major extension strategies are: acceptance s. Thecustomer/doctor is encouraged to use the product (important:scientific and medical evidence); use expansion s. Broadening indications,providing evidence for safe use in other patient groups/higher dosages, line extension a.s.o.; pr<strong>of</strong>ile enhancement s. Enhancement<strong>of</strong> the product-image; competitor response s. Prediction<strong>of</strong> and counteraction on competitor responses; cost-effectivenesss. Optimisation <strong>of</strong> effectiveness, minimisation <strong>of</strong> costs; → seealso formulation, innovative chemical entity, new chemicalentity, research and development.life event Major life events (such as illness, marriage, pregnancy,death <strong>of</strong> relatives, children, new job, quarrels with superiors, moveto a new home, vacations, loans taken, private bankruptcy etc.),can have effects on clinical outcomes and can bias results, esp. inquality <strong>of</strong> life studies; → see also bias.life-table analysis → see survival analysis.life-threatening FDA: “The patient was, in the view <strong>of</strong> the investigator,at immediate (emphasis added) risk <strong>of</strong> death from the reactionas it occurred, i.e., it does not include a reaction that, had it occurredin a more serious form, might have caused death.”Likert scale Usually a 3 or 5 point scale for categorical data (e.g.mild-moderate-sever); → see also visual analogue scale.Limulus Amebocyte lysate test (LAL) Test on the presence <strong>of</strong> bacterialendotoxins in drugs or devices in order to show effectiveness <strong>of</strong>depyrogenation techniques.linear analogue self assessment (LASA) → see visual analoguescale.linear correlation coefficient → see correlation coefficient.linear regression Process <strong>of</strong> fitting a straight line to two continuousvariables; mathematically: y = a + bx; b = regression coefficient;predicts, in contrast to correlation coefficient r, value <strong>of</strong> y from avalue <strong>of</strong> x; → see also correlation coefficient.line extension New commercial form <strong>of</strong> a marketed product, e.g. newdosage or application form, new galenical formulation a.s.o.; strategyused for life cycle management <strong>of</strong> a pharmaceutical product.liposome Vesicle constructed <strong>of</strong> phospholipid bilayers that allow thevesicles to mimic biological membranes; they contain aqueous

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!